Abstract: Methods and compositions for assessing ERCC5 gene expression in view of certain environmental exposures and determining the risk of an individual for developing one or more epithelial cancers are provided.
Type:
Grant
Filed:
January 7, 2009
Date of Patent:
December 27, 2011
Assignee:
President and Fellows of Harvard College
Abstract: The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. Also provided are probes for detecting the mutant sequences. Methods of identifying if an individual has a genotype containing one or more mutations in the CFTR gene are further provided.
Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with liver fibrosis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
Abstract: The present invention relates to a method of diagnosing a predisposition of a multiple sclerosis (MS) patient for responsiveness to a treatment of MS by administration of interferon-? (IFN-?) and/or interferon-? (IFN-?) and means to perform the method. Furthermore, the invention relates to a method of diagnosing a predisposition of a patient for developing multiple sclerosis (MS) and corresponding means.
Type:
Grant
Filed:
February 27, 2007
Date of Patent:
December 6, 2011
Assignee:
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
Abstract: A single nucleotide polymorphism occurring on a leptin receptor gene is analyzed and an inflammatory disease is examined on the basis of the analytical data. Further, a substance capable of changing the interaction between the leptin receptor and galectin-2 is selected to thereby screen a remedy for an inflammatory disease.
Abstract: Polynucleotides are provided which are useful as amplification primers and hybridization probes for detecting BS106 target sequence in a test sample. The primers and probes can be employed in amplification based methods for detecting the presence of BS106 sequences in a test sample. Additionally, the primers and probes can be used to perform homogeneous, real time reverse-transcriptase polymerase chain reaction to detect BS106 target sequence in a test sample.
Type:
Grant
Filed:
October 27, 2005
Date of Patent:
October 11, 2011
Assignee:
Abbott Laboratories
Inventors:
Natalie A. Solomon, Lisa A Roberts-Rapp
Abstract: A method for the detection of cytosine methylation in DNA samples is described. First, DNA is extracted from a sample and bound to a surface. In the second step, a genomic DNA sample is preferably treated with a bisulfite (=disulfite, hydrogen sulfite), such that all unmethylated cytosine bases are converted to uracil, while the 5-methylcytosine bases remain unchanged. In the third step of the method, one or more oligonucleotides is (are) hybridized to the treated DNA as primers. In the fourth step of the method, the hybridized primer(s) is or are elongated in a polymerase reaction. Here, labeled guanine nucleotides are preferably utilized which are essentially incorporated only if cytosine bases were still present in the treated DNA. Consequently, the extent of incorporation of guanine bases and thus also the number of incorporated labels is proportional to the methylation in the DNA sample under investigation.
Abstract: Methods are provided for identification of genes that are imprinted. In another embodiment methods are provided for identification and analysis of genes whose expression shows allelic imbalance. The expression products transcribed from genes that are present in the genome as two or more alleles may be distinguished by hybridization to an array designed to interrogate individual alleles. Genes whose transcription products are present in amounts that vary from expected are candidates for allelic imbalance, imprinting and imprinting errors.
Abstract: The present invention relates to new methods for diagnosing a pregnancy-associated disorder by analyzing fetal DNA present in the mother's blood. More specifically, this invention relies on the discovery that the maspin gene is differentially methylated in fetal DNA and in maternal DNA and provides these new diagnostic methods, which distinguish fetal DNA from maternal DNA and detect prenatal disorders based on abnormalities in fetal DNA level and methylation status.
Type:
Grant
Filed:
March 15, 2010
Date of Patent:
September 27, 2011
Assignee:
The Chinese University of Hong Kong
Inventors:
Yuk Ming Dennis Lo, Rossa Wai Kwun Chiu, Stephen Siu Chung Chim, Yu-kwan Tong, Chunming Ding
Abstract: A method of screening a subject for a proliferative disease risk factor comprises detecting the presence or absence of upregulation of the CLN3 gene in the subject. The upregulation of the CLN3 gene in the subject indicates the subject is at increased risk of developing a proliferative disease. Methods of screening compounds for the treatment of proliferative diseases based on the CLN3 gene and its product are also disclosed, along with methods of treating such diseases and vectors useful therefore.
Type:
Grant
Filed:
January 22, 2009
Date of Patent:
August 23, 2011
Assignee:
Duke University
Inventors:
Rose-Mary N. Boustany, Wei-Xing Guo, Andrea Amalfitano
Abstract: The invention concerns a method for identifying and/or cloning nucleic acid regions representing qualitative differences associated with alternative splicing events and/or with insertions, deletions located in RNA transcribed genome regions, between two physiological situations, comprising either hybridization of RNA derived from the test situation with cDNA's derived from the reference situation and/or reciprocally, or double-strand hybridization of cDNA derived from the test situation with cDNA's derived from the reference situation; and identifying and/or cloning nucleic acids representing qualitative differences. The invention also concerns compositions or banks of nucleic acids representing qualitative differences between two physiological situations, obtainable by the above method, and their use as probe, for identifying genes or molecules of interest, or still for example in methods of pharmacogenomics, and profiling of molecules relative to their therapeutic and/or toxic effects.
Type:
Grant
Filed:
November 19, 2009
Date of Patent:
August 23, 2011
Assignee:
ExonHit Therapeutics S.A.
Inventors:
Fabien Schweighoffer, Laurent Bracco, Bruno Tocque
Abstract: The invention relates generally to the gene, and mutations thereto, that are responsible for the disease hereditary hemochromatosis (HH). More particularly, the invention relates to the identification, isolation, and cloning of the DNA sequence corresponding to the normal and mutant HH genes, as well as the characterization of their transcripts and gene products. The invention also related to methods and the like for screening for HH homozygotes and further relates to HH diagnosis, prenatal screening and diagnosis, and therapies of HH disease, including gene therapeutics, protein and antibody based therapeutics, and small molecule therapeutics.
Type:
Grant
Filed:
February 19, 2009
Date of Patent:
August 16, 2011
Assignee:
Bio-Rad Laboratories, Inc.
Inventors:
Winston J. Thomas, Dennis T. Drayna, John N. Feder, Andreas Gnirke, David Ruddy, Zenta Tsuchihashi, Roger K. Wolff
Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with coronary heart disease and in particular stenosis and MI and response to drug treatment. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
Type:
Grant
Filed:
March 13, 2006
Date of Patent:
July 12, 2011
Assignee:
Celera Corporation
Inventors:
May M. Luke, James J. Devlin, Dov Shiffman
Abstract: The present invention provides CpG islands and GC rich regions and methods for identifying methylation states for these CpG islands and GC rich regions. The present invention also provides methods for identifying genes regulated by these CpG islands and GC rich regions, and provides methods for identifying a population of CpG islands and GC rich regions in a genome.
Type:
Grant
Filed:
December 2, 2002
Date of Patent:
June 21, 2011
Assignee:
The Johns Hopkins University School of Medicine
Abstract: This invention relates to nucleotide polymorphisms in the human Apo(a) gene and to the use of Apo(a) nucleotide polymorphisms in identifying whether a human subject will respond or not to treatment with acetylsalicylic acid.
Type:
Grant
Filed:
May 9, 2008
Date of Patent:
May 17, 2011
Assignees:
The Brigham and Women's Hospital, Inc., Applera Corporation
Inventors:
Paul Ridker, Daniel Chasman, Dov Shiffman
Abstract: The present invention relates to methods and compositions for predicting the risk of obesity. In particular, the present invention provides methods and compositions for determining a subject's risk of obesity based on the presence of polymorphisms in the growth hormone secretagogue receptor (GHSR).
Abstract: Provided is a multiple single nucleotide polymorphism (SNP) for colorectal cancer diagnosis, a microarray and a kit including a polynucleotide having the SNP, and a method of diagnosing colorectal cancer using the SNP. Early diagnosis of incidence or possibility of colorectal cancer can be effectively performed by using the method.
Type:
Grant
Filed:
April 3, 2006
Date of Patent:
April 26, 2011
Assignee:
Samsung Electronics Co., Ltd.
Inventors:
Seung-Hak Choi, Yun-Sun Nam, Jae-Heup Kim, Kyu-Sang Lee, Min-Sun Kim, Tae-Jin Ahn
Abstract: Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a OPRP genetic signature are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the genetic signature.
Type:
Grant
Filed:
October 13, 2010
Date of Patent:
April 26, 2011
Assignee:
Suregene, LLC
Inventors:
Timothy L. Ramsey, Bharat Mehrotra, Mark D. Brennan